Neurosense Therapeutics will meet with the FDA in early November to discuss plans for a Phase 3 trial to test PrimeC in ALS.

Woolsey received three new U.S. patents covering innovations related to ROCK inhibitor Bravyl (oral fasudil), its ...

A database with long-term ALS respiratory data has been made available to scientists worldwide, with the goal of accelerating research.

Columnist Dagmar Munn describes the frequent sensation of humming, which was among the early symptoms of her ALS.

Signs of angels come at the most unexpected — yet vital — moments in our lives, columnist Juliet Taylor writes.

Neither memantine nor trazodone was able to slow amyotrophic lateral sclerosis (ALS) disease progression in a platform ...

ALS symptom progression brings challenges, but for columnist Dagmar Munn, the key to living well with the disease is to be ...

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ...

After her late husband's diagnosis anniversary, columnist Juliet Taylor reflects on how grief became a heavy burden and a ...

The Scott-Morgan Foundation is launching a joint initiative that aims to use AI technologies to help improve communication ...

A combined analysis of data over years in patients in Phase 2 trials of supports benefits for those up to age 65 and moderate ...

The first patient has been dosed in an open-label Phase 1/2 clinical trial of AMT-162, uniQure's one-time gene therapy for ...